Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06842874 · 1 trial · 1 indication
Treatment-related AEs are any untoward medical occurrences attributed to study drug in a participant who received study drug.
The following parameters will be analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, lactate dehydrogenase, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid); electrolytes (sodium, potassium, chloride, calcium, phosphate, bicarbonate); clinical chemistry (glucose, creatine kinase); immunology (CRP); urinalysis (dipstick \[urine specific gravity, decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, bilirubin\], microscopy \[urine RBC, WBC, urate crystals, calcium, oxalate, miscellaneous \[urine mucus and leucocytes\]).
The following parameters will be analyzed for examination of vital signs: systolic blood pressure, diastolic blood pressure, and pulse rate.
Measurements of heart rate, PR interval, QT interval, QTc intervals, and QRS complex
Cardiac rhythms measured by continuous cardiac telemetry
A complete physical examination includes, at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A limited physical examination includes, at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant-reported symptoms.
| Arm | Type | Description |
|---|---|---|
| PF-06842874/Placebo | EXPERIMENTAL | Single dose administration of PF-06842874 or placebo |
| Relative Bioavailability | EXPERIMENTAL | Determination of relative bioavailability of modified-release formulation relative to immediate-release formulation |
| Name | Type | Description |
|---|---|---|
| PF-06842874 | DRUG | Single dose administration of PF-06842874 |
| Placebo | DRUG | Single dose administration of placebo |
| Relative Bioavailability | DRUG | Relative bioavailability assessment of modified-release formulation |
Inclusion Criteria: * Female participants of non-childbearing potential and male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, and cardiac monitoring. * Body mass index (BMI) of 17.5 to 30.5 kg/m2...
PF-06842874 is an investigational small molecule being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development for use in healthy participants. The drug is being studied to evaluate its safety, tolerability, and pharmacokinetics.
PF-06842874 is being studied for use in healthy participants. The purpose of the clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of the drug. It is an investigational small molecule and is not yet approved for any medical condition.
PF-06842874 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development.
PF-06842874 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
PF-06842874 has one completed clinical trial, identified as NCT04124653. This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of the drug in 44 healthy participants in the United States. The trial was randomized, double-blind, and controlled.
PF-06842874 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial, NCT04124653, was designed to evaluate safety, tolerability, and pharmacokinetics in healthy participants, but the drug has not been approved for any use.